by 
The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Neprilysin or neutral endopeptidase (NEP) is a zinc metalloproteinase enzyme that breaks down vasoactive peptides such as natriuretic peptides and kinins. Anti-neprilysin inhibitors act by preventing neprilysin from degrading natriuretic peptides, leading to vasodilation and natriuresis. Major products in the anti-neprilysin market are Sacubitril/Valsartan combination tablet marketed under the brand name Entresto by Novartis. Entresto is primarily indicated for the treatment of heart failure with reduced ejection fraction. The heart failure market represents a large unmet need, as the condition affects over 26 million people worldwide.
Market Dynamics:
Growing Prevalence of Heart Failure: The prevalence of heart failure is increasing rapidly across the world owing to factors such as aging population, prevalence of risk factors like diabetes, obesity, smoking, and lifestyle changes. As per the American Heart Association statistics, over 6.2 million adults in the U.S. suffer from heart failure, with around half a million new cases reported each year. The growing disease burden of heart failure is expected to drive the demand for improved treatment options like anti-neprilysin inhibitors.
Increased Efficacy of Anti-Neprilysin Therapies: Clinical trials have demonstrated the efficacy of anti-neprilysin inhibitors like sacubitril/valsartan in reducing cardiovascular mortality and hospitalization in heart failure patients. ENTRESO has proven non-inferiority to enalapril, the current standard of care, and superiority in reducing rates of cardiovascular death and hospitalization. The better outcomes offered by anti-neprilysin drugs is anticipated to boost their adoption over the forecast period.
Segment Analysis
The anti-Neprilysin market is segmented into type and application. Based on type, the market is segmented into racecadotril, thiorphan and others. Racecadotril dominates the type segment and accounts for over 50% market share. It has strong anti-secretory properties and is highly effective in reducing hypersecretion and diarrhea associated with various gastrointestinal disorders.
PEST Analysis
Political: The anti-Neprilysin market is regulated by various authorities like the FDA. Stringent regulations may impact the approval and commercialization of new drugs.
Economic: Rising healthcare expenditures and growing incidence of cardiovascular and renal diseases are driving growth of the anti-Neprilysin market. However, high R&D costs required for new drug development poses a challenge.
Social: Growing awareness about treatments of cardiovascular diseases is supporting the demand for anti-Neprilysin drugs. Also, increasing approvals of novel drugs offer improved treatment options.
Technological: Advancements in drug delivery technologies like nanotechnology have enabled development of drugs with improved efficacy and reduced side effects. This is positively impacting the anti-Neprilysin market.
Key Takeaways
The global anti-Neprilysin market is expected to witness high growth over the forecast period supported by increasing prevalence of cardiovascular diseases, approvals of novel drugs and technological advancements.
Regionally, North America dominates the market currently owing to developed healthcare infrastructure and major presence of key players. Europe and Asia Pacific are also promising markets and expected to grow at a fast pace during the forecast period.
Key players operating in the anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. BIOPROJET dominates the market with its flagship drug racecadotril. Novartis AG offers Entresto containing Sacubitril/Valsartan for treatment of heart failure. Pharmaleads SA is developing novel Neprilysin inhibitors for indications like Alzheimer’s disease. Theravance Biopharm focuses on developing respiratory drugs leveraging Neprilysin inhibition platform.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
